LungLife AI

Company Profile

Company website
Pharmaceuticals and Biotechnology (Biotechnology)
LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company’s core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan.

Investor Access

26 Sep
Event information
Management will hold a presentation for Investors through the digital platform, Investor Meet Company, on Monday 26th September 2022 at 4:30pm relating to the interim results for the six months ended 30 June 2022.  Investors can sign up to Investor Meet Company for free, by clicking here
Monday 26th September 2022 at 4:30pm
Financial Calendar
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*September
Interim Results*TBC

* Months based on previous announcements of this kind